The Bacterial Pneumonia Therapeutics Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Bacterial Pneumonia Therapeutics Market: Drivers and Challenges
Increase in bacterial resistance of streptococcus bacteria, HIV associated pneumonia, rise in prevalence of pneumonia and government initiatives are major factors driving the growth of bacterial pneumonia therapeutics market over the forecast period. According to national statistics UK, in 2013, 5% of deaths in England and Wales are associated due to pneumonia and influenza. Lack of new drugs and improper diagnosis of pneumonia conditions are hindering the growth of this market over the forecast period.
Bacterial Pneumonia Therapeutics Market: Key Players
Some of the players in global bacterial pneumonia market are AstraZeneca plc, Nabriva Therapeutics AG, SetLance SRL, Merck & Co., Inc, Daiichi Sankyo Company, Limited, GlaxoSmithKline Plc, Pfizer Inc., Sanofi Pasteur SA and others
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/14299
Bacterial Pneumonia Therapeutics Market: Regional Overview
America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America is projected to dominate the over forecast period owing to high research activities on novel molecules and high deaths related to bacterial pneumonia conditions are attributing the growth of this market. Asia-Pacific is expected to dominate the market due to increase in healthcare infrastructure and high prevalence of pneumonia in South Asia countries
To View TOC of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/toc/14299